Results 171 to 180 of about 1,306,054 (295)

SAMe, Choline, and Valproic Acid as Possible Epigenetic Drugs: Their Effects in Pregnancy with a Special Emphasis on Animal Studies. [PDF]

Pharmaceuticals (Basel), 2022
Ornoy A, Weinstein-Fudim L, Becker M.
europepmc   +1 more source

National Drugs Advisory Board annual report, 1990.

, 1990
The National Drugs Advisory Board was established by the Minister for Health in 1966 by the National Drugs Advisory Board (Establishment) Order 1966 (5.1. No.163 of 1966) under the Health (Corporate Bodies) Act 1961.
National Drugs Advisory Board (NDAB)
core  

Stress Hyperglycemia Drives CD4+ T Cell PANoptosis and Postoperative Organ Injury via Monocyte‐Derived Succinate

Advanced Science, EarlyView.
High glucose is linked to reduced succinate dehydrogenase activity in CD14+ monocytes, accompanied by succinate accumulation and extracellular release. Extracellular succinate exacerbates mitochondrial ROS production and mtDNA release in CD4+ T cells. Cytosolic mtDNA then activates Z‐DNA binding protein 1 (ZBP1) and engages ZBP1‐associated inflammatory
Shuai Zhao, Xuemei Miao, Wei Luo, Tao Liu, Yang Wang, Jiaying Li, Di Fu, Weiyun Shen, Yan Luo, Kang Chen, Ruping Dai, Hui Li   +11 more
wiley   +1 more source

Bivalent chromatin as a therapeutic target in cancer: An in silico predictive approach for combining epigenetic drugs. [PDF]

PLoS Comput Biol, 2021
Alarcón T, Sardanyés J, Guillamon A, Menendez JA.   +3 more
europepmc   +1 more source

Nanoparticle‐Mediated TIPE1 mRNA Delivery Enhances Paclitaxel Sensitivity in Triple‐Negative Breast Cancer by Modulating RAB7A Ubiquitination‐Associated Stability and Autophagy

Advanced Science, EarlyView.
TIPE1m NPs nanoparticles restore TIPE1 expression, promote RAB7A ubiquitination and degradation, suppress autophagic flux, and resensitize paclitaxel‐resistant triple‐negative breast cancer to therapy. ABSTRACT Acquired paclitaxel (PTX) resistance remains a major obstacle in triple‐negative breast cancer (TNBC) treatment.
Wei Hu, Qishuai Chen, Yan Ma, Yang Liu, Xianing Dong, Wenjuan Wei, Jianxin Du, Shusheng Qiu, Maojin Tian, Peiqing Zhao   +9 more
wiley   +1 more source

The power and the promise of epigenetic drugs in oncology. [PDF]

Front Genet
Scandolara TB, Siqueira IVM, Ribeiro Pinto LF, Soares-Lima SC.   +3 more
europepmc   +1 more source

The Epigenetics of Drug Addiction

International Journal of Pharmaceutical Sciences Review and Research, 2023
Zoha Shaik, Suffah Naaz, Fariha Maheen, Basavaraju Sreevani   +3 more
openaire   +1 more source

Identification of drug sensitive gene motifs using "epigenetic profiles" derived from bioinformatics databases

, 2016
The use of epigenetic modifying drugs such as DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) is becoming more common in the treatment of cancer.
Nelson, Jonathan M.
core  

Polymer Concepts in Cellular Function

Advanced Science, EarlyView.
Miao Yu, Shikha Dhiman, Dorothee Dormann, Frauke Gräter, Katja Luck, Friederike Schmid, Andreas Walther, Edward A. Lemke   +7 more
wiley   +1 more source

Copper‐Doped Prussian Blue Nanozymes With Hyaluronic Acid‐Mediated Targeting Alleviate Oxidative Stress and Regulate Cholesterol Handling for Atherosclerosis Therapy

Advanced Science, EarlyView.
CuPB@HA is a CD44‐associated, plaque‐targeted nanozyme that alleviates oxidative stress, inflammation, and lipid accumulation in macrophages. By reducing CD36‐dependent lipid uptake and promoting ABCA1/ABCG1‐mediated cholesterol handling, it improves macrophage function, preferentially accumulates in atherosclerotic lesions, reduces plaque burden, and ...
Jianliang Ou, Ruihua Ji, Qinglu Zang, Mingkang Wang, Lingling Zhou, Yingliang Wei, Di Yang, Yue Wu, Hongxu Zhu, Jianrong Wu, Xiaojun Cai, Wenxian Du, Junjie Cheng, An Zeng, Yuehua Li   +14 more
wiley   +1 more source